Abstract: A high-frequency coil component includes a sealing portion containing a resin and a plurality of hollow particles, and a coil portion composed of a wound conductive wire. The coil portion is sealed in the sealing portion. The resin includes a low-dielectric resin having a relative permittivity ?r1 of 2.00 or more and less than 3.00 at 23±2° C. A mass of the resin is represented by Mr. A total mass of the plurality of hollow particles is represented by Mp. Mr/(Mr+Mp) is 25% or more and 85% or less.

Abstract: A coil component includes a coil configured of a winding, an exterior body provided to cover the coil, and a terminal part configured to be continuous with the winding. A proximal end portion of the terminal part is buried in the exterior body. A distal end portion ahead of the proximal end portion is bent from the proximal end portion and located outside a mounting surface of the exterior body along the mounting surface.

Abstract: An electronic component includes an element body, an electric element embedded inside the element body, and an electrode terminal connected to the electric element so as to be exposed to an outer surface of the element body. The electrode terminal includes a terminal body continuously and integrally formed with a wire of the electric element embedded inside the element body and extending in a planar shape along a main surface of the element body. The wire is drawn out to an outside of the element body from the main surface of the element body to form the electrode terminal.

Abstract: An electronic component includes an element body and an electrode terminal. The electrode terminal includes a terminal body extending in a planar shape along a main surface of the element body, and at least one of an outward protrusion continuously and integrally formed with the terminal body and protruding outside the main surface and an inward protrusion continuously and integrally formed with the terminal body and extending inside of the element body from the main surface.

Abstract: A biological information input system includes: a measurement instrument having a communication function and configured to measure biological information of a person under measurement; and a first terminal device having a communication function capable of communicating with the communication function of the measurement instrument, and configured to receive, via the communication function, the biological information associated with the person under measurement and measured by the measurement instrument. The biological information input system displays a screen with which a person having authority to approve the biological information approves first data including the biological information and information related to the person under measurement.

Abstract: A coil device 1 comprises a coil 10, a T-shaped core 20 including a columnar portion 21 around which the coil 10 is disposed and a flange 22 formed at a first end 21a of the columnar portion 21 in an axial direction thereof, and an exterior body 30 covering the coil 10 and the columnar portion 21 and made of an exterior material including magnetic particles and a resin. The core 20 is provided with a recess 40 including at least one of a first recess 41 or a second recess 42. The first recess 41 extends between the first end 21a and a second end 21b of the columnar portion 21 in the axial direction. The second recess 42 extends from an inner side towards an outer side of the flange 22.

Abstract: This arcuate magnet piece includes: coupling side surfaces which are coupled with other adjacently joined arcuate magnet pieces; a curved inner peripheral surface; and a curved outer peripheral surface which faces the inner peripheral surface. The coupling side surfaces include tip surfaces which intersect, at prescribed angles, tangents to the direction of curvature of the outer peripheral surface. The coupling side surfaces are polarized such that, in cases when the gaps formed with the coupling side surfaces of the other arcuate magnet pieces are disposed so as to be substantially parallel, the magnetic poles of the other joined arcuate magnet pieces are different.

Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.

Abstract: This arcuate magnet piece includes: coupling side surfaces which are coupled with other adjacently joined arcuate magnet pieces; a curved inner peripheral surface; and a curved outer peripheral surface which faces the inner peripheral surface. The coupling side surfaces include tip surfaces which intersect, at prescribed angles, tangents to the direction of curvature of the outer peripheral surface. The coupling side surfaces are polarized such that, in cases when the gaps formed with the coupling side surfaces of the other arcuate magnet pieces are disposed so as to be substantially parallel, the magnetic poles of the other joined arcuate magnet pieces are different.

Abstract: A lens holding unit is held so that it can relatively move with respect to a base part to a direction vertical to an optical axis direction. The lens holding unit has a lens holder, a magnet part, and a spring. The lens holder has a first coil. The magnet part has a first magnet part which includes a first face facing to the first coil and a second magnet part which includes a second face vertical to the first face and constitutes a magnetic domain different from that of the first magnet part. These first magnet part and second magnet part are integrated.

Abstract: A lens holding device includes a movable part having a coil attached to a lens holder holding a lens and includes a magnet part arranged around an outer peripheral side of the movable part so as to face the coil. The lens holding device includes a support part which supports the movable part so as to move relatively and a spring which connects the movable part and the support part resiliently. The magnet part includes a resin and has an alignment part which positions the spring.

Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.

Abstract: An injection molding composition includes a ferrite powder which is a collection of ferrite particles, a first binder and a second binder, wherein a softening point of the second binder is lower than that of the first binder, a weight and a specific surface area of the ferrite powders are represented by Wp and S, and a weight and a density of the first binder and the second binder is represented by Wb1, Wb2, and Db1, Db2, and a hypothetical thickness Tb1 of the first binder is 0.6 to 3.0, and a hypothetical thickness Tb2 of the second binder is 5.0 to 16.0. In the composition, it is preferable that coated ferrite particles covering the outer circumference of the ferrite particles with the first binder and the second binder exist. Tb1 [nm]=(Wb1×103)/(Db1×Wp×S)??formula (1) Tb2 [nm]=(Wb2×103)/(Db2×Wp×S)??formula (2).

Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.

Abstract: A lens holding device includes a movable part having a coil attached to a lens holder holding a lens and includes a magnet part arranged around an outer peripheral side of the movable part so as to face the coil. The lens holding device includes a support part which supports the movable part so as to move relatively and a spring which connects the movable part and the support part resiliently. The magnet part includes a resin and has an alignment part which positions the spring.

Abstract: A lens holding unit is held so that it can relatively move with respect to a base part to a direction vertical to an optical axis direction. The lens holding unit has a lens holder, a magnet part, and a spring. The lens holder has a first coil. The magnet part has a first magnet part which includes a first face facing to the first coil and a second magnet part which includes a second face vertical to the first face and constitutes a magnetic domain different from that of the first magnet part. These first magnet part and second magnet part are integrated.

Abstract: An injection molding composition, having a small fluctuation characteristic and a better characteristic, is provided. The above composition is the injection molding composition comprising a ferrite powder which is a collection of ferrite particles, a first binder and a second binder. A weight and a specific surface area of the ferrite powders are represented by Wp and S, and a weight and a density of the first binder and the second binder is represented by Wb1, Wb2, and Db1, Db2. A hypothetical thickness Tb1 of the first binder is 2.0 to 15.0, and a hypothetical thickness Tb2 of the second binder is 16.5 to 32.0. In the composition, it is preferable that coated ferrite particles coating the outer circumference of the ferrite particles with the first binder and the second binder exist.

Abstract: An injection molding composition includes a ferrite powder which is a collection of ferrite particles, a first binder and a second binder, wherein a softening point of the second binder is lower than that of the first binder, a weight and a specific surface area of the ferrite powders are represented by Wp and S, and a weight and a density of the first binder and the second binder is represented by Wb1, Wb2, and Db1, Db2, and a hypothetical thickness Tb1 of the first binder is 0.6 to 3.0, and a hypothetical thickness Tb2 of the second binder is 5.0 to 16.0. In the composition, it is preferable that coated ferrite particles covering the outer circumference of the ferrite particles with the first binder and the second binder exist.

Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.

Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.